Ignite Creation Date:
2025-12-26 @ 11:47 AM
Ignite Modification Date:
2026-03-12 @ 6:27 AM
Study NCT ID:
NCT02437916
Status:
TERMINATED
Last Update Posted:
2022-11-08
First Post:
2015-04-03
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety Study of AMG 228 to Treat Solid Tumors
Sponsor:
Amgen
Organization:
Study Overview
Official Title:
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status:
TERMINATED
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: